JOINT FILING AGREEMENTJoint Filing Agreement • April 7th, 2017 • Capital Royalty L.P. • Surgical & medical instruments & apparatus
In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the common stock, par value $0.001 per share, of Valeritas Holdings, Inc., and further agree that this Joint Filing Agreement be included as an Exhibit to such joint filing. In evidence thereof, the undersigned hereby execute this Joint Filing Agreement.
EXHIBIT A JOINT FILING AGREEMENTJoint Filing Agreement • July 13th, 2023 • CR Group L.P. • Surgical & medical instruments & apparatus
In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock of T2 Biosystems, Inc. and further agree that this agreement be included as an exhibit to such filing. Each party to the agreement expressly authorizes each other party to file on its behalf any and all amendments to such statement. Each party to this agreement agrees that this joint filing agreement may be signed in counterparts.
VALERITAS, INC. THIRD AMENDED AND RESTATED VOTING AGREEMENTVoting Agreement • April 7th, 2017 • Capital Royalty L.P. • Surgical & medical instruments & apparatus • New York
This Third Amended and Restated Voting Agreement (the “Agreement”) is made and entered into as of January 29, 2016, by and among (i) Valeritas, Inc., a Delaware corporation (the “Company”), (ii) the holders of the Company’s issued and outstanding shares of Series AB Preferred Stock of the Corporation, par value $0.00001 per share (“Series AB Preferred Stock”), Series AA Preferred Stock of the Corporation, par value $0.00001 per share (“Series AA Preferred Stock”), Series D Preferred Stock of the Corporation, par value $0.00001 per share (“Series D Preferred Stock”, and together with Series AB Preferred Stock and Series AA Preferred Stock, “Preferred Stock”) and Common Stock of the Corporation, par value $0.00001 (“Common Stock”) listed on Schedule A attached hereto (collectively, the “Investors”), and (iii) the holders of the Company’s issued and outstanding shares of Common Stock and holders of options to acquire the Company’s Common Stock listed on Schedule B attached hereto or who h
EXHIBIT A JOINT FILING AGREEMENTJoint Filing Agreement • August 14th, 2023 • CR Group L.P. • Surgical & medical instruments & apparatus
In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock of Avinger, Inc. and further agree that this agreement be included as an exhibit to such filing. Each party to the agreement expressly authorizes each other party to file on its behalf any and all amendments to such statement. Each party to this agreement agrees that this joint filing agreement may be signed in counterparts.
EXHIBIT A JOINT FILING AGREEMENTJoint Filing Agreement • March 15th, 2024 • CR Group L.P. • Surgical & medical instruments & apparatus
In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock of Avinger, Inc. and further agree that this agreement be included as an exhibit to such filing. Each party to the agreement expressly authorizes each other party to file on its behalf any and all amendments to such statement. Each party to this agreement agrees that this joint filing agreement may be signed in counterparts.
JOINT FILING AGREEMENTJoint Filing Agreement • May 21st, 2020 • CR Group L.P. • Surgical & medical instruments & apparatus
In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the common stock, par value $0.001 per share, of TearLab Corporation, and further agree that this Joint Filing Agreement be included as an Exhibit to such joint filing. In evidence thereof, the undersigned hereby execute this Joint Filing Agreement.
AGREEMENT AS TO JOINT FILING OF SCHEDULE 13GAgreement as to Joint Filing of Schedule 13g • December 28th, 2018 • Capital Royalty L.P. • Pharmaceutical preparations
The undersigned hereby agree that the Schedule 13G relating to the common stock of Strongbridge Biopharma plc, and any further amendments thereto, to which this Agreement as to Joint Filing of Schedule 13G is attached as an exhibit is filed on behalf of each of them pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.
JOINT FILING AGREEMENTJoint Filing Agreement • April 19th, 2024 • CR Group L.P. • Surgical & medical instruments & apparatus
